#1.2
10	123
CASRN	Name	Prostatic Intraepithelial Neoplasia | CTD_CHEMICALS_DISEASES | 3.95e-03	SPERMATOGENIC FAILURE, X-LINKED, 2 | CTD_CHEMICALS_DISEASES | 4.21e-03	Poisoning | CTD_CHEM2DISEASE | 1.57e-04	Genetic Toxicity -mouse lymphoma | LEADSCOPE_TOXICITY | 8.01e-03	Genetic Toxicity -In vitro composite | LEADSCOPE_TOXICITY | 2.84e-05	KEGG:00380|Tryptophan metabolism | CTD_PATHWAY | 5.45e-07	Cecal Neoplasms | CTD_CHEMICALS_DISEASES | 3.30e-05	Status Epilepticus | CTD_CHEMICALS_DISEASES | 3.16e-02	Precancerous Conditions | CTD_CHEMICALS_DISEASES | 3.36e-02	Esophageal Squamous Cell Carcinoma | CTD_CHEMICALS_DISEASES | 1.46e-02	Genetic Toxicity -In vitro chrom. ab. CHL | LEADSCOPE_TOXICITY | 5.98e-05	Myocardial Reperfusion Injury | CTD_CHEMICALS_DISEASES | 3.24e-02	KEGG:00980|Metabolism of xenobiotics by cytochrome P450 | CTD_PATHWAY | 6.68e-05	Benz(a)Anthracenes | MESH | 3.62e-05	Arteriosclerosis | CTD_CHEM2DISEASE | 4.05e-02	Necrosis | CTD_CHEM2DISEASE | 3.14e-02	Reproductive Toxicity-SHE | LEADSCOPE_TOXICITY | 2.87e-04	Kidney Diseases | CTD_CHEM2DISEASE | 2.36e-02	Genetic Toxicity -drosophila SLRL | LEADSCOPE_TOXICITY | 3.93e-03	Acid Phosphatase Deficiency | CTD_CHEMICALS_DISEASES | 1.48e-05	Hypertrophy | CTD_CHEM2DISEASE | 4.70e-03	ring:fused_PAH_anthracene | TOXPRINT_STRUCTURE | 3.72e-09	ring:fused_PAH_pyrene | TOXPRINT_STRUCTURE | 3.72e-05	MELAS Syndrome | CTD_CHEMICALS_DISEASES | 1.25e-02	Carcinoma, Pancreatic Ductal | CTD_CHEMICALS_DISEASES | 6.25e-03	Facies | CTD_CHEMICALS_DISEASES | 4.85e-02	Genetic Toxicity -UDS rat hepatocytes | LEADSCOPE_TOXICITY | 2.25e-04	OCT1 inhibition at 100uM | MULTICASE_TOX_PREDICTION | 8.68e-06	Silicosis | CTD_CHEMICALS_DISEASES | 9.31e-03	Musculoskeletal Pain | CTD_CHEMICALS_DISEASES | 4.76e-02	ring:fused_PAH_acenaphthylene | TOXPRINT_STRUCTURE | 1.07e-02	Immune System Diseases | CTD_CHEM2DISEASE | 9.76e-04	KEGG:01100|Metabolic pathways | CTD_PATHWAY | 1.69e-02	Congenital Abnormalities | CTD_CHEM2DISEASE | 1.97e-03	Genetic Toxicity -SCE in vitro other cells | LEADSCOPE_TOXICITY | 4.12e-03	Immunologic Deficiency Syndromes | CTD_CHEM2DISEASE | 5.90e-07	Polycyclic Hydrocarbons, Aromatic | MESH | 1.69e-12	Bronchiectasis | CTD_CHEMICALS_DISEASES | 1.56e-02	KEGG:00830|Retinol metabolism | CTD_PATHWAY | 1.89e-03	Inflammatory Bowel Diseases | CTD_CHEMICALS_DISEASES | 3.66e-02	Local lymph node assay, mouse, moderate sensitizers (EC3 < 10%) | MULTICASE_TOX_PREDICTION | 1.02e-04	Spherocytosis, Hereditary | CTD_CHEMICALS_DISEASES | 1.04e-03	KEGG:00190|Oxidative phosphorylation | CTD_PATHWAY | 1.26e-02	Carcinoma, Ductal, Breast | CTD_CHEMICALS_DISEASES | 3.30e-02	Hepatitis, Alcoholic | CTD_CHEMICALS_DISEASES | 2.43e-02	HIV Infections | CTD_CHEMICALS_DISEASES | 4.11e-02	Salmonella Infections, Animal | CTD_CHEMICALS_DISEASES | 3.00e-03	AHR | CTD_CHEM2GENE_25 | 3.30e-09	Neurodevelopmental Disorders | CTD_CHEMICALS_DISEASES | 1.63e-03	activation_EndoRS | HTS_ACTIVE | 3.29e-04	Lung Injury | CTD_CHEMICALS_DISEASES | 3.28e-02	Pyrenes | MESH | 1.31e-02	Reproductive Toxicity- sperm mouse | LEADSCOPE_TOXICITY | 3.26e-05	Sleep Disorders, Circadian Rhythm | CTD_CHEMICALS_DISEASES | 1.09e-03	Hydrocarbons | MESH | 7.47e-06	KEGG:00982|Drug metabolism - cytochrome P450 | CTD_PATHWAY | 5.76e-03	Hydrocarbons, Cyclic | MESH | 5.64e-07	Liver Diseases | CTD_CHEMICALS_DISEASES | 4.28e-02	ring:fused_PAH_benz(a)anthracene | TOXPRINT_STRUCTURE | 2.17e-05	COVID-19 | CTD_CHEMICALS_DISEASES | 2.29e-02	ring:fused_PAH_phenanthrene | TOXPRINT_STRUCTURE | 3.18e-14	Liver Cirrhosis | CTD_CHEMICALS_DISEASES | 4.17e-02	Genetic Toxicity -E. coli | LEADSCOPE_TOXICITY | 7.47e-04	MACULAR DEGENERATION, AGE-RELATED, 14 | CTD_CHEMICALS_DISEASES | 2.40e-02	Genetic Toxicity -UDS human lymphocytes | LEADSCOPE_TOXICITY | 5.33e-06	Infertility, Male | CTD_CHEMICALS_DISEASES | 2.85e-02	Common Variable Immunodeficiency | CTD_CHEMICALS_DISEASES | 4.46e-03	Phenanthrenes | MESH | 4.22e-02	Human plasma protein binding, %bound | MULTICASE_TOX_PREDICTION | 7.67e-04	BE0003721 | TOXINS_TARGETS | 3.45e-07	ring:fused_PAH_benzophenanthrene | TOXPRINT_STRUCTURE | 3.24e-03	Spinal Cord Injuries | CTD_CHEMICALS_DISEASES | 4.61e-02	Local lymph node assay, mouse, weak sensitizers (EC3 < 100%) | MULTICASE_TOX_PREDICTION | 5.19e-03	Local lymph node assay, mouse, extreme sensitizers (EC3 < 1%) | MULTICASE_TOX_PREDICTION | 1.17e-05	Genetic Toxicity -SCE in vitro CHO | LEADSCOPE_TOXICITY | 4.16e-03	Skin Neoplasms | CTD_CHEM2DISEASE | 1.12e-02	Pulmonary Emphysema | CTD_CHEMICALS_DISEASES | 9.19e-03	Hypophosphatasia | CTD_CHEMICALS_DISEASES | 4.45e-02	agonism_RSP | HTS_ACTIVE | 1.37e-02	Sarcoma | CTD_CHEM2DISEASE | 1.19e-03	Uterine Cervical Neoplasms | CTD_CHEMICALS_DISEASES | 1.76e-02	Genetic Toxicity -salmonella | LEADSCOPE_TOXICITY | 5.40e-08	Gastroesophageal Reflux | CTD_CHEMICALS_DISEASES | 4.74e-02	BCRP inhibition at 10uM | MULTICASE_TOX_PREDICTION | 2.16e-07	Human Adverse Cardiological Effects -bradycardia | LEADSCOPE_TOXICITY | 8.96e-04	Polycyclic Compounds | MESH | 1.58e-09	Disease Progression | CTD_CHEMICALS_DISEASES | 5.75e-03	Nervous System Malformations | CTD_CHEM2DISEASE | 4.30e-02	Hepatolenticular Degeneration | CTD_CHEMICALS_DISEASES | 3.14e-03	BE0000372 | TOXINS_TARGETS | 2.32e-19	ring:aromatic_benzene | TOXPRINT_STRUCTURE | 5.53e-03	Hyperoxia | CTD_CHEMICALS_DISEASES | 7.01e-08	KEGG:05323|Rheumatoid arthritis | CTD_PATHWAY | 2.14e-02	BE0000132 | TOXINS_TARGETS | 6.95e-04	MRP1 inhibition at 10uM | MULTICASE_TOX_PREDICTION | 1.64e-06	ring:fused_[6_6]_naphthalene | TOXPRINT_STRUCTURE | 1.92e-15	KEGG:00140|Steroid hormone biosynthesis | CTD_PATHWAY | 8.87e-05	Lung Neoplasms | CTD_CHEM2DISEASE | 3.49e-02	Leishmaniasis, Visceral | CTD_CHEMICALS_DISEASES | 3.04e-02	RCA fetal death, mouse | MULTICASE_TOX_PREDICTION | 2.22e-02	Meier-Gorlin syndrome | CTD_CHEMICALS_DISEASES | 4.35e-02	antagonism_AR/full/run2 | HTS_ACTIVE | 2.30e-02	AHR | TOXINS_TARGETS | 8.82e-06	Liver Neoplasms | CTD_CHEM2DISEASE | 3.79e-02	BE0004796 | TOXINS_TARGETS | 2.92e-09	BE0001111 | TOXINS_TARGETS | 2.78e-02	Liver Neoplasms, Experimental | CTD_CHEM2DISEASE | 2.13e-03	Dermatitis, Atopic | CTD_CHEMICALS_DISEASES | 1.25e-03	Cardiovascular Abnormalities | CTD_CHEM2DISEASE | 3.92e-02	Hydrocarbons, Aromatic | MESH | 1.87e-07	Genetic Toxicity -microbial | LEADSCOPE_TOXICITY | 1.64e-08	Adenoma | CTD_CHEM2DISEASE | 7.54e-03	GNMT | TOXINS_TARGETS | 1.22e-16	Genetic Toxicity -UDS | LEADSCOPE_TOXICITY | 5.40e-03	Neuronopathy, Distal Hereditary Motor, Type V | CTD_CHEMICALS_DISEASES | 1.16e-02	Osteogenesis Imperfecta, Type IV | CTD_CHEMICALS_DISEASES | 5.59e-03	Reproductive Toxicity-cell transformation | LEADSCOPE_TOXICITY | 2.51e-04	Extent of human metabolism, % | MULTICASE_TOX_PREDICTION | 1.42e-03	Glaucoma 3, primary infantile, B | CTD_CHEMICALS_DISEASES | 1.11e-02	MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1 | CTD_CHEMICALS_DISEASES | 4.29e-02	RCA survival post-implantation, rodent | MULTICASE_TOX_PREDICTION | 1.47e-02	Advanced Sleep-Phase Syndrome, Familial | CTD_CHEMICALS_DISEASES | 2.92e-02	Varicose Veins | CTD_CHEMICALS_DISEASES | 1.61e-04
56-55-3		1	1	1	1	1	1	0	1	0	0	1	0	1	1	0	0	1	0	1	0	1	1	0	1	1	0	1	1	1	1	0	0	0	0	1	1	1	0	0	1	1	0	0	1	1	1	0	0	0	0	1	0	1	1	1	0	1	0	1	1	1	0	1	1	1	1	0	0	1	1	0	0	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	0	0	1	1	1	1	1	1	1	1	0	0	1	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1
83-32-9		0	0	0	1	0	0	0	0	1	1	1	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	1	0	1	0	0	0	1	0	0	0	1	0	1	1	0	0	1	0	1	0	1	0	1	1	0	1	0	1	1	0	1	1	0	0	1	1	0	0	1	1	1	0	1	0	0	0	0	1	1	1	0	1	1	0	0	1	1	1	0	0	1	1	0	0	1	0	0	0	1	0	1	0	0	1	0	1	1	0	1	1	0	0	1	1	1	0	0	0	0
191-24-2		0	0	0	1	1	0	0	0	0	1	1	0	0	1	0	0	1	0	0	0	0	1	1	0	0	0	0	1	1	0	0	0	0	0	1	0	1	0	0	0	1	1	0	0	0	1	0	1	1	1	0	0	1	0	1	0	1	0	0	0	1	1	1	1	1	0	0	0	1	1	0	1	1	1	1	0	0	0	0	0	0	1	0	1	0	1	0	0	0	1	1	1	0	0	1	1	0	0	0	0	0	0	1	0	1	0	0	1	0	1	1	0	1	0	0	1	1	1	0	0	0	0	1
53-70-3		1	0	1	1	1	1	0	0	1	0	1	0	1	1	1	1	1	0	1	0	0	1	0	0	1	0	1	1	0	0	0	0	1	0	1	1	1	0	1	0	1	1	0	0	0	1	0	0	0	1	0	0	1	1	1	1	1	1	1	0	1	0	1	0	1	1	0	0	1	1	0	1	1	1	1	1	0	1	1	1	0	1	0	1	1	1	0	0	1	1	1	1	0	1	1	1	1	1	0	1	0	0	1	1	1	0	0	0	0	1	1	1	1	1	0	0	1	1	1	0	1	1	1
85-01-8		0	0	1	0	1	1	1	1	0	0	1	1	1	0	0	0	1	1	0	1	0	0	0	1	0	0	0	1	0	0	0	0	1	1	1	0	1	1	1	0	1	0	0	1	1	0	0	1	0	0	0	0	1	0	1	1	1	1	0	0	1	0	0	0	0	0	0	1	1	1	0	0	1	1	1	0	1	0	0	0	1	1	1	1	1	1	0	0	0	1	1	1	0	0	1	1	1	0	0	1	0	1	1	0	1	1	0	1	1	1	1	0	1	0	0	0	1	1	0	0	1	0	0
120-12-7		0	0	0	0	1	1	1	1	1	1	0	1	1	0	0	0	1	1	0	1	0	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0	1	0	1	1	1	0	0	0	0	0	1	1	0	1	0	0	1	0	1	0	1	1	0	1	0	1	1	0	1	0	1	0	1	1	0	0	1	0	1	0	0	0	1	0	0	1	1	1	1	1	1	0	1	1	1	0	1	0	1	1	1	0	1	0	0	1	1	0	1	0	0	1	0	1	1	0	1	0	0	0	1	1	1	0	0	0	0
218-01-9		1	1	0	0	1	1	1	1	1	0	1	1	1	0	0	1	1	1	0	0	0	0	0	0	1	1	0	1	0	1	0	1	1	0	1	1	1	1	1	1	1	0	0	0	0	0	0	1	1	0	1	0	1	1	1	1	1	0	0	0	1	1	0	0	0	1	1	1	1	1	1	1	1	1	1	0	0	0	1	0	1	1	0	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	0	1	0	0	1	0	1	0	1	0	0	1	1	0	1	0	1	1	1	1	0	1	1	0	1
206-44-0		1	0	1	0	0	1	1	1	0	0	0	1	1	0	0	0	1	0	1	0	1	0	0	1	0	0	0	1	1	0	1	0	1	0	1	0	1	0	0	0	1	0	1	1	0	0	1	1	1	1	1	0	1	0	1	1	1	0	0	1	0	0	1	0	1	0	0	0	1	1	0	1	1	1	1	0	1	0	0	0	1	1	0	1	0	1	0	0	1	1	1	1	1	1	1	1	0	0	1	1	1	1	1	0	1	0	0	0	0	1	1	0	1	1	0	0	1	1	0	1	0	0	0
50-32-8		0	0	0	1	1	1	0	0	1	1	1	0	1	0	1	1	1	1	1	0	1	1	1	0	0	1	1	1	1	0	0	1	1	1	1	1	1	0	1	0	1	1	1	0	0	0	0	1	1	0	0	1	1	0	1	1	1	0	1	0	1	1	1	0	1	0	0	0	1	1	1	0	1	1	1	1	0	0	1	1	0	1	0	1	1	1	1	1	0	1	1	0	1	1	1	1	1	1	0	1	1	1	1	1	1	0	1	0	0	1	1	1	1	1	0	0	1	1	0	0	1	0	0
129-00-0		1	0	1	1	1	1	1	0	0	1	1	1	1	0	0	1	1	0	0	1	0	0	1	1	1	0	0	1	0	1	0	1	1	1	1	0	1	1	1	1	1	0	1	0	1	1	1	1	0	0	1	1	1	0	1	1	1	1	0	0	1	0	0	0	0	1	1	0	1	1	0	0	1	1	1	0	1	0	0	0	0	1	0	1	0	1	1	1	1	1	1	1	1	0	1	1	1	0	1	0	0	1	0	0	1	1	1	1	0	1	1	0	0	0	0	0	1	1	0	1	0	0	0
